Skip to main content
. 2017 Jun 20;8:362. doi: 10.3389/fphar.2017.00362

FIGURE 1.

FIGURE 1

Combined use of GABA and sitagliptin in STZ-induced T1D mouse model generates additive effects on improving glucose tolerance. (A) A chart shows the mouse experiment design. (B) Longitudinal blood glucose levels in the four groups of mice defined as Water (diabetic control), GABA (GABA treatment), Sita (sitagliptin treatment), and GABA+Sita (GABA plus sitagliptin treatment). (C) Longitudinal blood glucose levels in the four groups of mice defined as HD-STZ+Water (diabetic control), HD-STZ+GABA (GABA treatment), HD-STZ+Sita (sitagliptin treatment), and HD-STZ+GABA+Sita (GABA plus sitagliptin treatment). (D) IPGTT performed at 5-weeks-old (defined as baseline) as well as at 11-weeks-old. (E) Area under curve (AUC) for (D). (F) IPITT performed at 5-weeks-old (defined as baseline) as well as at 11-weeks-old. (G) Area under curve (AUC) for (F). For (D–G), n = 20 for the baseline and n = 5 for each of the four groups of mice. Data are mean ± SD. ∗P < 0.05, ∗∗P < 0.01. ϕP < 0.05, ϕϕP < 0.01, ϕϕϕP < 0.001 vs. diabetic control group; &P < 0.05, &&&P < 0.001 vs. GABA treated group; $P < 0.05, $$P < 0.01 vs. sitagliptin treated group.